Authors
Latest:
GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast CancerPatients with breast cancer experience significant weight loss after using GLP-1 receptor agonists, highlighting potential benefits for obesity management in this population.
Latest:
Future Perspectives on MRD Testing in Colorectal CancerThe expert panel concludes its discussion with a focus on the future of MRD testing in colorectal cancer, highlighting the treatment landscape’s current strengths and challenges.
Latest:
Closing Remarks on the Future of Dermatologic Care in NSCLCPanelists discuss how the field is shifting from reactive to proactive management of dermatologic adverse events, with future developments potentially including new topical treatments and integrated dermatology support within oncology practices.
Latest:
Updates in Surgical Management of the AxillaAxillary management of patients with breast cancer such as sentinel lymph node biopsy have evolved substantially over the past 30 years.
Latest:
Integrative Oncology in Young Women With Breast CancerYancey Warren, Jr, MD, MAT, and colleagues investigate the use of integrative oncology services among young women with breast cancer.
Latest:
Darolutamide/ADT Yields OS Benefit in mHSPC Across All Disease VolumesFindings from the phase 3 ARASENS trial indicate that darolutamide plus androgen-deprivation therapy and docetaxel should be considered a new standard of care for metastatic hormone-sensitive prostate cancer.
Latest:
Ferdinandos Skoulidis, MD, PhD, MRCP, Discusses Exciting Research in the Lung Cancer Field From ASCO 2021Ferdinandos Skoulidis, MD, PhD, MRCP, details what he was most excited to learn about at 2021 ASCO.
Latest:
Pediatric Locally Advanced Synovial Sarcoma: What Would Be the Best Treatment Option?KEY POINTS • Synovial sarcomas are often mistreated with unplanned tumor resection. • Attention from specialists early in the course of SS can minimize the risk of recurrence, metastases, and the necessity for resurgery, all of which are increased with unplanned tumor resection. • Chemotherapy alone does not provide sufficient local control of the tumor. • Resurgery, in conjunction with radiotherapy and chemotherapy, is the best choice of management for this patient.
Latest:
Exploring Next-Line Options in HER2- MSS Gastric CancerExperts discuss other therapies or clinical trials that might be explored after trastuzumab deruxtecan, particularly for patients with HER2-positive microsatellite-stable (MSS) adenocarcinoma and progression on multiple lines of therapy.
Latest:
Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With CancerImmunocompromised individuals face ongoing COVID-19 risks despite vaccination, highlighting the need for tailored public health strategies and innovative therapies.
Latest:
The Role of Artificial Intelligence in Palliative Oncology: Zeroing in on Hematologic MalignanciesAI revolutionizes palliative oncology by enhancing prognostication, symptom management, and personalized care for patients with hematologic malignancies.
Latest:
Input From a Multidisciplinary Team of Medical Providers is ‘Necessary’ to Manage Contralateral Breast Cancer, Says ExpertIt takes a team of physicians from multidisciplinary backgrounds to best manage patients with contralateral breast cancer, according to a Mayo Clinic Expert.
Latest:
Non-BCMA Targeting Bispecifics in MM and Future Directions in CareBefore closing out their discussion with key takeaways, expert panelists highlight novel non-BCMA targeting bispecifics in the setting of multiple myeloma.
